The discovery has shed light on a complex blood interaction that has likely always been present in humans but was unnoticed ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Financing led by new Investors Fåhraeus Startup and Growth and EIC FundHELSINKI, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Aplagon, a ...

Background Neurointerventional devices, particularly laser-cut thin-strut stents made of self-expanding nickel-titanium alloy, are increasingly utilized for endovascular applications in intracranial ...

Sickle cell trait does not cause individuals to die of physical exertion or heat-related injuries without rhabdomyolysis, according to a findings of a systematic literature review. In this episode ...

Historically, those patients had been treated with heparin drip and then transitioned to oral anticoagulation. We aim to analyze the effect of intravenous heparin in patients with acute ischemic ...

Tinzaparin is contraindicated in patients with active major bleeding, patients with (or with a history of) heparin-induced thrombocytopenia, and patients with hypersensitivity to tinzaparin.